Anzeige
Mehr »
Mittwoch, 13.08.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PP3A | ISIN: IL0011595993 | Ticker-Symbol: 154
Tradegate
12.08.25 | 21:59
12,205 Euro
+0,16 % +0,020
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
INMODE LTD Chart 1 Jahr
5-Tage-Chart
INMODE LTD 5-Tage-Chart
RealtimeGeldBriefZeit
11,98512,25009:43
11,98512,25009:13
PR Newswire
438 Leser
Artikel bewerten:
(2)

InMode Ltd.: InMode Response Letter to DOMA by Moshe Mizrahy, CEO, Dated May 28, 2025

YOKNEAM, Israel, May 28, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today sent a letter to DOMA Perpetual Capital Management LLC ("DOMA") CEO and CIO Pedro Escudero in response to issues presented in his public letter dated May 9, 2025.

The letter can be viewed here

The full text of the letter follows:

May 28, 2025

Mr. Pedro Escudero
CEO and CIO
DOMA, Perpetual Capital Management LLC

Dear Mr. Escudero,

This letter is in response to your letter dated May 9, 2025.

First, I would like to thank you for voting for me to be re-elected to the Board of Directors. I really appreciate your vote of confidence and trust. I understand from this that you believe that my contribution to InMode's Board of Directors is important.

I am answering your letter as the CEO of InMode and presume that Dr. Michael Anghel -the Chairman of InMode - will answer your letter as well.

With regards to the claims you specified in your letter:

Buyback - As you know Pedro, in the last 12 months - we bought-back $412M of InMode shares, and in the last 2.5 years - we bought back $508M of InMode shares. Our goal is to return capital to our shareholders in the most tax-efficient manner possible. I believe that our buy-back program is reasonable for both the company as well as its shareholders and takes into consideration the tax rules in Israel.

Moving production capacity out of Israel - I don't know how many industrial companies you have managed during your career, but InMode's supply chain and manufacturing team has many years of experience in manufacturing medical equipment in Israel from many aspects, including regulation, quality and cost. As I wrote to you in my letter dated March 6, 2025 - InMode is not a mass-production company and therefore the manufacturing capacity must be in close proximity to the engineering, R&D and logistic management teams. We have been (and still are) enduring a war that has taken place in Israel over the last two years, and yet we have supplied every platform to every country/destination (90 countries) on time, without compromising our quality.

Sales Organization in North America - as I explained in my letter dated March 6, 2025, all of our sales management positions are manned, and work in a most professional manner. Unfortunately, the slowdown in our business in North America, which is mainly due to macro-economic factors and difficulty in financing medical capital equipment are the main reasons for the slowdown in our business in North America, and not the management of our sales organization.

My performance as CEO - I believe that writing that my management style is "reckless and antagonistic", with "dismal leadership and poor performance as CEO" is unbased and unethical. I am the co-founder of this company and have been managing it since day one along with my co-founder - Dr. Michael Kreindel - in a very "lean and mean" manner. I will leave the decision regarding myself to my Board of Directors.

Regards,
Moshe Mizrahy
CEO, InMode Ltd.

About InMode

InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio frequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.

Forward-Looking Statements

The information in this press release includes forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or InMode's future financial or operating performance, including the 2025 revenue projection described above. Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. In some cases, you can identify these statements because they contain words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," "would" and similar expressions that concern our expectations, strategic plans or intentions. Forward-looking statements are based on management's current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Consequently, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements included in InMode's Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 04, 2025, and our future public filings. InMode undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which pertain only as of the date of this press release.

Company Contact:

Yair Malca
Chief Financial Officer
Phone: (949) 305-0108
Email: [email protected]

Investor Relations Contact:

Miri Segal
MS-IR LLC
Email: [email protected]

Logo - https://mma.prnewswire.com/media/1064477/5298285/InMode_Logo.jpg

SOURCE InMode Ltd.

© 2025 PR Newswire
Tech-Aktien mit Crash-Tendenzen
Künstliche Intelligenz, Magnificent Seven, Tech-Euphorie – seit Monaten scheint an der Börse nur eine Richtung zu existieren: nach oben. Doch hinter den Rekordkursen lauert eine gefährliche Wahrheit. Die Bewertungen vieler Tech-Schwergewichte haben historische Extremniveaus erreicht. Shiller-KGV bei 39, Buffett-Indikator auf Allzeithoch – schon in der Dotcom-Ära war der Markt kaum teurer.

Hinzu kommen euphorische Anlegerstimmung, IPO-Hypes ohne Substanz, kreditfinanzierte Wertpapierkäufe in Rekordhöhe und charttechnische Warnsignale, die Erinnerungen an 2000 und 2021 wecken. Gleichzeitig drücken geopolitische Risiken, Trumps aggressive Zollpolitik und saisonale Börsenschwäche auf die Perspektiven.

Die Gefahr: Aus der schleichenden Korrektur könnte ein rasanter Crash werden – und der könnte vor allem überbewertete KI- und Chipwerte hart treffen.

In unserem kostenlosen Spezial-Report zeigen wir Ihnen, welche Tech-Aktien am stärksten gefährdet sind und wie Sie Ihr Depot vor dem Platzen der Blase schützen könnten.

Holen Sie sich den neuesten Report!

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.